Esperion secures $50M royalty financing from Athyrium for acquisition

April 2, 2026 4:05 PM

Esperion Therapeutics Inc. (NASDAQ: ESPR) announced a $50 million royalty financing agreement with funds managed by Athyrium Capital Management to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found